Trial Profile

Phase 1b/2a of NVG-291 in patients Alzheimer's disease

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NVG 291 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Sponsors NervGen Pharma

Most Recent Events

19 Nov 2025 According to a NervGen Pharma media release, the company announced a non-brokered private placement to certain institutional and accredited investors and intends to use the proceeds to advance its NVG-291 clinical development program.
02 Aug 2022 According to a NervGen Pharma media release, study design will be presented at the 2022 Alzheimer's Association International Conference (AAIC).
18 Oct 2021 According to a NervGen Pharma media release, this study is expected to begin in 2H 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com